Who founded Cellevate?

Cellevate was founded by Maximilian Ottosson in 2025.

Who are Cellevate's investors?

Cellevate's investors include Industrifonden, Onsight Ventures, European Investment Bank, EIC, European Innovation Council Fund.

How much funding has Cellevate raised?

Cellevate has disclosed $25K raised across 1 of its 6 known rounds.

Where is Cellevate headquartered?

Cellevate is headquartered in Long Beach, US.

Cellevate

Long Beach, US · Founded 2025 · Delaware corporation · 21 employees on LinkedIn · 5 known investors

Find your way into Cellevate

Paths you didn't know you had: your email and LinkedIn already hold routes to the Cellevate team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Cellevate develops Cellevat3d nanofiber-based microcarriers and cell culture systems for upstream bioprocessing, used in viral vector, viral vaccine, and stem cell production by gene therapy and biopharmaceutical organizations. Founded as a spinout from NanoLund and Prof. Lars Montelius's group, the company focuses on commercializing nanofiber cell culture technology.

Advanced Manufacturing Biotech Deep Tech Medical Devices New Materials

Founders & leadership

Cellevate was founded in 2025 by Maximilian Ottosson.

Maximilian Ottosson FounderMaximilian Ottosson co-founded Cellevate, a nanofiber-based cell culture company spun out from NanoLund, where he held roles including CEO and COO and oversaw company building, fundraising, and commercial operations. He brings over a decade of experience in deeptech and biotech commercialization.

Clint MonfortNamed on SEC filing

Investors · 5

Industrifonden✓ confirmed by CellevateStockholm · $960K – $4.8M

How we know: Industrifonden's portfolio page · the company's own site · funding news · cellevate.com · Not right? Tell us

Onsight Ventures✓ confirmed by CellevateInnsbruck · $216K – $2.2M

How we know: the company's own site · Onsight Ventures's portfolio page · funding news · cellevate.com · Not right? Tell us

European Investment Bank✓ confirmed by CellevateLuxembourg

How we know: the company's own site · Not right? Tell us

EICreportedOrinda

How we know: funding news · Not right? Tell us

European Innovation Council Fundreported

How we know: funding news · cellevate.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$25K disclosed across 1 of 6 rounds · 2023–2026

Undisclosed amountSeed FinancingJun 2026
Source ↗
Undisclosed amountSeed FinancingOct 2023 · 3 sources
Industrifonden (lead), European Innovation Council Fund (EIC Fund), Onsight Ventures
Source ↗

▶$25KraisedJun 2025 · 1 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Clint MonfortExecutive Officer, Director, Promoter

Offering amount: $2M
Amount sold: $25K
First sale: May 2025
Incorporated: Corporation, Delaware, 2025
Federal exemptions: 04, 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

AgilentAgilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors. The company operates through three segments: Life Sciences and Diagnostics Markets (which includes contract manufacturing services for oligonucleotide therapeutics and pathology solutions), Agilent CrossLab (providing lab services and automation), and Applied Markets (offering analytical instruments and software).

CellaresCellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.

Celldex Therapeutics, Inc.Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.

CellphireCellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.

Companies working in the same space as Cellevate.

In the news

Cellevate | Cellevate raises 39 million SEK in Seed Financing to accelerate their global commercial launchcellevate.com · Oct 2023

Frequently asked questions

What does Cellevate do?: Cellevate develops Cellevat3d nanofiber-based microcarriers and cell culture systems for upstream bioprocessing, used in viral vector, viral vaccine, and stem cell production by gene therapy and biopharmaceutical organizations. Founded as a spinout from NanoLund and Prof. Lars Montelius's group, the company focuses on commercializing nanofiber cell culture technology.
Who founded Cellevate?: Cellevate was founded by Maximilian Ottosson in 2025.
Who are Cellevate's investors?: Cellevate's investors include Industrifonden, Onsight Ventures, European Investment Bank, EIC, European Innovation Council Fund.
How much funding has Cellevate raised?: Cellevate has disclosed $25K raised across 1 of its 6 known rounds.
Where is Cellevate headquartered?: Cellevate is headquartered in Long Beach, US.